Galligan Anna, Wallace Roslyn, Krishnamurthy Balasubramanian, Kay Thomas W H, Sachithanandan Nirupa, Chiang Cherie, Sandhu Shahneen, Hicks Rodney J, Iravani Amir
Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, VIC 3065, Australia.
Department of Medicine, St Vincent's Hospital Medical School, University of Melbourne, Melbourne, VIC 3010, Australia.
Cancers (Basel). 2023 Dec 11;15(24):5803. doi: 10.3390/cancers15245803.
FDG-PET/CT used for immune checkpoint inhibitor (ICI) response assessment can incidentally identify immune-related adverse events (irAEs), including thyroiditis. This study aimed to correlate the time course of FDG-PET/CT evidence of thyroiditis with clinical and biochemical evolution of thyroid dysfunction.
A retrospective review was performed by two independent blinded nuclear medicine physicians (NMPs) of thyroidal FDG uptake in 127 patients who underwent PET/CT between January 2016 and January 2019 at baseline and during treatment monitoring of combination ICI therapy for advanced melanoma. Interobserver agreement was assessed and FDG-PET/CT performance defined by a receiver-operating characteristic (ROC) curve using thyroid function tests (TFTs) as the standard of truth. Thyroid maximum standardized uptake value (SUVmax) and its temporal changes with respect to the longitudinal biochemistry were serially recorded.
At a median of 3 weeks after commencing ICI, 43/127 (34%) had a diagnosis of thyroiditis established by abnormal TFTs. FDG-PET/CT was performed at baseline and at a median of 11 weeks (range 3-32) following the start of therapy. ROC analysis showed an area under the curve of 0.87 (95% CI 0.80, 0.94) for FDG-PET/CT for detection of thyroiditis with a positive predictive value of 93%. Among patients with biochemical evidence of thyroiditis, those with a positive FDG-PET/CT were more likely to develop overt hypothyroidism (77% versus 35%, < 0.01). In the evaluation of the index test, there was an almost perfect interobserver agreement between NMPs of 93.7% (95% CI 89.4-98.0), kappa 0.83.
Increased metabolic activity of the thyroid on routine FDG-PET/CT performed for tumoral response of patients undergoing ICI therapy is generally detected well after routine biochemical diagnosis. Elevation of FDG uptake in the thyroid is predictive of overt clinical hypothyroidism and suggests that an ongoing robust inflammatory response beyond the initial thyrotoxic phase may be indicative of thyroid destruction.
用于免疫检查点抑制剂(ICI)反应评估的氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)可偶然发现包括甲状腺炎在内的免疫相关不良事件(irAE)。本研究旨在将甲状腺炎的FDG-PET/CT证据的时间进程与甲状腺功能障碍的临床和生化演变相关联。
由两名独立的盲法核医学医师(NMP)对2016年1月至2019年1月期间在基线以及晚期黑色素瘤联合ICI治疗的治疗监测期间接受PET/CT检查的127例患者的甲状腺FDG摄取情况进行回顾性分析。评估观察者间的一致性,并以甲状腺功能测试(TFT)作为金标准,通过受试者操作特征(ROC)曲线确定FDG-PET/CT的性能。连续记录甲状腺最大标准化摄取值(SUVmax)及其相对于纵向生化指标的时间变化。
在开始ICI治疗后的中位3周时,43/127(34%)的患者通过异常的TFT被诊断为甲状腺炎。在基线以及治疗开始后的中位11周(范围3-32周)时进行了FDG-PET/CT检查。ROC分析显示,FDG-PET/CT检测甲状腺炎的曲线下面积为0.87(95%CI 0.80, 0.94),阳性预测值为93%。在有甲状腺炎生化证据的患者中,FDG-PET/CT阳性的患者更有可能发展为明显的甲状腺功能减退(77%对35%,<0.01)。在指标测试评估中,NMP之间的观察者间一致性几乎完美,为93.7%(95%CI 89.4-98.0),kappa值为0.83。
在为接受ICI治疗的患者进行肿瘤反应的常规FDG-PET/CT检查时,甲状腺代谢活性增加通常在常规生化诊断后很久才被发现。甲状腺FDG摄取增加可预测明显的临床甲状腺功能减退,并表明在最初的甲状腺毒症阶段之后持续存在的强烈炎症反应可能预示着甲状腺破坏。